Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Related Keywords

China ,Australia ,Tsadal ,Kyongsang Bukto ,South Korea ,Shanghai ,Hong Kong ,Singapore ,Kevin Lynch ,Asia Pacific ,Peter Qian ,Li Xiao Qiu ,Karyopharm Therapeutics Inc ,Company Annual ,Antengene Corporation ,Drug Administration ,Hong Kong Stock Exchange ,Prnewswire Antengene Corporation Limited ,Antengene Corporation Limited ,Swatch ,Corporation Limited ,Chief Medical ,B Cell Lymphoma ,East Asia ,Non Hodgkin Lymphoma ,Karyopharm Therapeutics ,Patients Beyond ,Asia Pacific Region ,Greater China ,Annual Report ,Hong Kong Stock ,Intj Hematol ,Hematol Oncol ,Diagnostics Concepts ,Politics ,Health ,Cancer ,Lymphoma ,Pr Newswire ,